CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Austin, Texas, United States and 20 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Austin, Texas, United States and 46 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Austin, Texas, United States and 53 other locations
in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...
Phase 3
Austin, Texas, United States and 117 other locations
of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...
Phase 2
Austin, Texas, United States and 77 other locations
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...
Phase 3
Austin, Texas, United States and 202 other locations
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin A...
Phase 3
Austin, Texas, United States and 46 other locations
cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian...
Phase 3
Austin, Texas, United States and 148 other locations
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...
Phase 3
Austin, Texas, United States and 196 other locations
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...
Phase 2
Austin, Texas, United States and 16 other locations
Clinical trials
Research sites
Resources
Legal